These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1354 related articles for article (PubMed ID: 24292625)

  • 1. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
    Krönke J; Udeshi ND; Narla A; Grauman P; Hurst SN; McConkey M; Svinkina T; Heckl D; Comer E; Li X; Ciarlo C; Hartman E; Munshi N; Schenone M; Schreiber SL; Carr SA; Ebert BL
    Science; 2014 Jan; 343(6168):301-5. PubMed ID: 24292625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
    Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
    Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel mechanism of lenalidomide activity.
    Fink EC; Ebert BL
    Blood; 2015 Nov; 126(21):2366-9. PubMed ID: 26438514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
    Petzold G; Fischer ES; Thomä NH
    Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
    Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
    Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular mechanism of thalidomide analogs in hematologic malignancies.
    Lindner S; Krönke J
    J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide.
    Abdulkarim H; Zourob M; Siaj M
    Sci Rep; 2020 Jun; 10(1):10424. PubMed ID: 32591583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4
    Sievers QL; Gasser JA; Cowley GS; Fischer ES; Ebert BL
    Blood; 2018 Sep; 132(12):1293-1303. PubMed ID: 30042095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
    Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
    Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition.
    Liu Y; He X; Sui Y; Yu R; Xu G
    FEBS Lett; 2015 Aug; 589(17):2233-40. PubMed ID: 26183205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.
    Gao S; Geng C; Song T; Lin X; Liu J; Cai Z; Cang Y
    J Biol Chem; 2017 Mar; 292(9):3683-3691. PubMed ID: 28087699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma cells' capacity to decompose H
    Sebastian S; Zhu YX; Braggio E; Shi CX; Panchabhai SC; Van Wier SA; Ahmann GJ; Chesi M; Bergsagel PL; Stewart AK; Fonseca R
    Blood; 2017 Feb; 129(8):991-1007. PubMed ID: 28028022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UBE2G1 governs the destruction of cereblon neomorphic substrates.
    Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M
    Elife; 2018 Sep; 7():. PubMed ID: 30234487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
    Guirguis AA; Ebert BL
    Curr Opin Cell Biol; 2015 Dec; 37():61-7. PubMed ID: 26512454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review].
    Fan WJ; Fan ZQ; Yang MJ; Pan YZ; Bai H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1240-1243. PubMed ID: 30111438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide induces degradation of IKZF1 and IKZF3.
    Krönke J; Hurst SN; Ebert BL
    Oncoimmunology; 2014; 3(7):e941742. PubMed ID: 25610725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.